Health CareHealth Care Equipment & Services
  • Price (USD)154.22
  • Today's Change-0.55 / -0.36%
  • Shares traded1.41m
  • 1 Year change+35.44%
  • Beta1.0317
Data delayed at least 15 minutes, as of Sep 20 2021 21:10 BST.
More ▼
Take Survey
Help shape our future virtual events & community services
Take part in our survey for a chance to win a free 3-month standard gift subscription.

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Quest Diagnostics Inc grew revenues 22.15% from 7.73bn to 9.44bn while net income improved 66.78% from 858.00m to 1.43bn.
Gross margin41.74%
Net profit margin20.40%
Operating margin24.47%
Return on assets17.45%
Return on equity38.16%
Return on investment20.31%
More ▼

Cash flow in USDView more

In 2020, Quest Diagnostics Inc did not generate a significant amount of cash. However, the company earned 2.01bn from its operations for a Cash Flow Margin of 21.25%. In addition the company used 772.00m on investing activities and also paid 1.27bn in financing cash flows.
Cash flow per share19.77
Price/Cash flow per share7.15
Book value per share48.35
Tangible book value per share-19.00
More ▼

Balance sheet in USDView more

Quest Diagnostics Inc has a Debt to Total Capital ratio of 39.99%, a lower figure than the previous year's 68.94%.
Current ratio1.38
Quick ratio1.26
Total debt/total equity0.6798
Total debt/total capital0.3999
More ▼

Growth rates in USD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 4.25% and 70.66%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Healthcare Facilities industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)1.95%
Div growth rate (5 year)8.50%
Payout ratio (TTM)13.76%
EPS growth(5 years)16.56
EPS (TTM) vs
TTM 1 year ago
More ▼
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.